LitAlert ~~ GeneLit.com

    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.

    • The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination.
    • Schipani F, Manerba M, Marotta R, Poppi L, Gennari A, Rinaldi F, Armirotti A, Farabegoli F, Roberti M, Di Stefano G, Rocchia W, Girotto S, Tirelli N, Cavalli A.
    • Int J Mol Sci. 2022 Jul 28;23(15):8338. doi: 10.3390/ijms23158338.

    • High grade acinic cell carcinoma of the breast with clear cytoplasm mimics clear cell carcinoma in a BRCA1 mutation carrier: a case report and review of the literature on the molecular analysis.
    • Min L, Qiao H, Hongkai Z.
    • Histol Histopathol. 2022 Jul 27:18501. doi: 10.14670/HH-18-501. Epub ahead of print.

    • Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis.
    • Nguyen-Sträuli BD, Baum J, Meyer-Wilmes P, Kreklau A, Buschmann C, El Ouardi N, Fotopoulou C, Hummel M, Chekerov R, Braicu E, Sehouli J, Pietzner K.
    • Int J Gynecol Cancer. 2022 Jul 27:ijgc-2022-003637. doi: 10.1136/ijgc-2022-003637. Epub ahead of print.

    • Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.
    • Chan VKY, Yang R, Wong ICK, Li X.
    • Front Pharmacol. 2022 Jul 11;13:891149. doi: 10.3389/fphar.2022.891149.

    • Evolution in adjuvant treatment of ovarian carcinoma [Évolution des traitements adjuvants des cancers de l'ovaire].
    • Pautier P.
    • Rev Prat. 2022 Jun;72(6):633-637. French.